Videothoracoscopic talc poudrage in primary spontaneous pneumothorax: A single-institution experience in 861 cases  by Cardillo, Giuseppe et al.
General Thoracic Surgery Cardillo et al
G
TSVideothoracoscopic talc poudrage in primary spontaneous
pneumothorax: A single-institution experience in 861 cases
Giuseppe Cardillo, MD, FETCS,a Francesco Carleo, MD,a Roberto Giunti, MD,a Luigi Carbone, MD,aSalvatore Mariotta, MD,c Lorenzo Salvadori, MD,a Lea Petrella, PhD,b and Massimo Martelli, MDaFrom the Thoracic Surgery Unit, Carlo For-
lanini Hospital, Azienda Ospedaliera San
Camillo-Forlanini,a the Department of
“Studi Geoeconomici, Linguistici, Statis-
tici, Storici per l’Analisi Regionale,”b and
the Department of Pneumology, S. Andrea
Hospital,c Medicine University of Rome
“La Sapienza,” Rome, Italy.
Read at the Eighty-fifth Annual Meeting of
The American Association for Thoracic
Surgery, San Francisco, Calif, April 10-13,
2005.
Received for publication April 8, 2005; re-
visions received Oct 11, 2005; accepted for
publication Oct 20, 2005.
Address for reprints: Giuseppe Cardillo,
MD, The Thoracic Surgery Unit, Carlo
Forlanini Hospital–Via Portuense 332,
00149 Rome, Italy (E-mail: gcardillo@
scamilloforlanini.rm.it).
J Thorac Cardiovasc Surg 2006;131:322-8
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgery
S. Treggiari, G. Cardillo, R. Giunti, L. Salvadori,
M. Martelli, M. DiMartino, L. Carbone,
M. Lopergolo. (left to right)doi:10.1016/j.jtcvs.2005.10.025
322 The Journal of Thoracic and CardioObjective: We sought to evaluate the outcome of 861 patients treated with video-
thoracoscopic talc poudrage for primary spontaneous pneumothorax.
Methods: From September 1995 through January 2004, a total of 861 patients (578
male, 283 female, mean age 28.6 years) underwent videothoracoscopy for recurrent
and complicated primary spontaneous pneumothorax. Patients were treated with
videothoracoscopic talc poudrage only (group A: Vanderschueren’s stage I, 196
patients; stage II, 112 patients) or videothoracoscopic talc poudrage plus stapling of
the blebs/bullae (group B: stage III, 391 patients; stage IV 162 patients). Follow-up
included clinical interview and chest radiography (805 patients). In 26 patients
(follow-up longer than 5 years), respiratory function was investigated to determine
residual volume and diffusing lung capacity.
Results: No operative deaths occurred. No patient had adult respiratory distress
syndrome. Postoperative complications occurred in 29 patients (3.36%). The con-
version rate to an open procedure was 0.46% (4/861). After a mean follow-up of
52.5 months, 14 patients had recurrences (1.73%). The recurrence rate was 2.41%
(7/290) in group A and 1.359% (7/515) in group B (2 value: 1.207389; P:.27; odds
ratio: 0.56; 95% confidence interval: 0.20-1.62). Results of respiratory function tests
were within normal ranges (80% or more of predictive value) in all 26 patients.
Conclusions: Videothoracoscopic talc poudrage achieves a high success rate in the
treatment of primary spontaneous pneumothorax with a very low morbidity rate.
Recurrences show a statistically significant relationship (P:.037) with smoking
habits.
Primary spontaneous pneumothorax (PSP) is a significant global problemoccurring in otherwise healthy young subjects with a reported incidence of 18to 28 cases per 100,000 population per year for men and 1.2 to 6 cases per
100,000 population per year for women.1,2 Smoking plays a role in the development
of PSP3: the lifetime risk in healthy smoking men may be as much as 12% compared
with 0.1% in nonsmoking men.3 PSP recurs in up to 25% of the cases after a first
episode and up to 50% after a second episode, especially in the first 2 years after the
initial episode.4 Treatment options for PSP include observation, manual aspiration,
intercostal tube drainage, and surgery.1,2,4
There is clear evidence that patients with a first episode of PSP should be
treated with intercostal drainage in most cases and with observation or manual
aspiration in a very few selected cases. The surgical option should be offered in
case of a second ipsilateral pneumothorax, first contralateral pneumothorax,
bilateral spontaneous pneumothorax, spontaneous hemothorax, persistent air
leak (5-7 days of tube drainage), failure to completely re-expand after inter-
costal drainage, and for professions at risk (aircraft personnel, sportsmen, scuba
divers).1,2
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TSSurgical options include open thoracotomy with bleb
resection and pleurectomy or videothoracoscopy (VATS)
with bleb resection plus pleural abrasion or talc pleurodesis.
A recent review by Sedrakyan and associates5 comparing
only randomized trials found VATS to be associated with a
shorter length of hospital stay or use of pain medication than
thoracotomy, with a comparable complication profile and
success rate. As regards as the method of choice for obtain-
ing pleurodesis, most authors6,7 prefer parietal pleurectomy
or pleural abrasion, although some concern still exists with
talc poudrage either because of the potential side effects of
talc or because of a reported relatively high failure rate.
In this article we evaluate the short- and intermediate-
term results of 861 patients treated with VATS talc
poudrage for PSP in a 9-year period. A special emphasis is
paid to side effects of the talc.
Methods
From September 1, 1995, to January 30, 2004, out of 2956 VATS
operations performed at the Unit of Thoracic Surgery, Carlo For-
lanini Hospital in Rome, 861 patients (29.12%) underwent VATS
treatment of PSP. No patient with HIV infection or cystic fibrosis
is included in the present series. Patient characteristics are shown
in Table 1. The diagnosis was made by conventional chest radio-
graphs. In 92 cases (10.68%) chest high-resolution computerized
tomography scans were performed. Preoperative investigation in-
cluded complete blood cell count, renal function tests, and elec-
trocardiograms. Indications for surgery are shown in Table 2.
Intraoperative staging was done according to Vanderschueren’s
classification8: stage I, no endoscopic abnormalities; stage II,
pleuropulmonary adhesions; stage III, blebs/bullae less than 2 cm;
stage IV, bullae more than 2 cm. The surgical protocol was as
follows: stage I, talc poudrage only; stage II, lysis of all adhesions
and talc poudrage; stages III and IV, stapling of the blebs/bullae
plus talc poudrage. Talc was selected according to the Italian
Abbreviations and Acronyms
PSP  primary spontaneous pneumothorax
VATS videothoracoscopy
TABLE 1. Patients characteristics
No. %
Total patients 861 100
Male 578 67.13
Female 283 32.87
Mean age (y) 28.6
Median age (y) 28
Range (y) 12-49
Smokers 511 59.35
Male smokers 361 70.64
Female smokers 150 17.42
The Journal of Thoracistandards (Farmacopea Italiana Ufficiale): (length of the fibers 
50 m). After surgery, patients underwent clinical interview and
chest radiography in our outpatient clinic at 1 month, 3 months,
and every 12 months postoperatively up to November 30, 2004.
Patients were asked to subjectively grade the severity of any
residual paresthesia (defined as any numbness or disordered sen-
sation causing chest wall discomfort that was distinguishable from
normal postoperative wound pain) on a 10-point analog scale (with
1 being minimal discomfort and 10 being the worst discomfort
imaginable): paresthesia was graded as mild (1-3), moderate (4-7),
and severe (8-10).9
Recurrent pneumothorax is defined as a pneumothorax greater
than 10% of the hemithorax in size. Twenty-six patients with no
recurrences underwent pulmonary function tests to evaluate forced
expiratory volume in 1 second, vital capacity, residual volume,
Tiffenau index, residual volume/total lung capacity, and diffusing
capacity for carbon monoxide by single breath test.
The research was approved by the Institutional Review Board
of Carlo Forlanini Hospital and informed consent was obtained
from each patient.
Statistical Analysis
Data were analyzed with NCSS 2004 (Number Cruncher
Statistical Systems, Kaysville, Utah). The 2 test was used
to ascertain the significance of association between two
categorical variables. The unpaired Student t test was used
to assess the significance between the mean of patients’ age
with or without recurrence of disease. The Farrington-
Manning test was performed to compute the confidence
intervals and hypothesis tests for the odds ratio. The overall
freedom from recurrence in the two groups A and B was
estimated by Kaplan-Meier survival curves and differences
by the log-rank test.
Operative Technique
All operations were performed with the patient under gen-
eral anesthesia using a double-lumen endotracheal Carlens
tube and one-lung ventilation. The patient was placed and
prepared as for a posterolateral thoracotomy. The first inci-
sion was always placed below the tip of the scapula in the
fifth or sixth intercostal space. A 0-degree, 10 mm video-
thoracoscope was introduced through a thoracoport. One or
TABLE 2. Indications for surgery
No. of patients
Ipsilateral recurrent pneumothorax 792
Persistent air leak after intercostal drainage 23




First contralateral pneumothorax 9
Bilateral spontaneous pneumothorax 4
Professions at risk 1two other thoracoports were placed under endoscopic guid-
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spontaneous pneumothorax. The lung was inspected during
gentle ventilation with saline in the pleural cavity to detect
blebs/bullae and air leaks. Blebs/bullae were treated by
minimal wedge resection with the endoscopic stapler (SCB
45, Ethicon Endosurgery, Cincinnati, Ohio). In case of
minimal air leak or bleeding along the suture line, fibrin
glue was used (Tissucol; Baxter, Deerfield, Mass). Talc
poudrage was accomplished by nebulization in the pleural
cavity of 2 g of asbestos-free sterilized talc.
Results
There were no postoperative (30-day) deaths. No intraop-
erative complications were reported. No patient required
blood transfusion. Mean operative time was 14  8 min-
utes. The conversion rate to an open procedures was 0.46%
(4/861 cases). The reason for conversion was extensive
pleural adhesions with obliteration of the pleural cavity.
Staging according to Vanderschueren’s classification was as
follows: stage I, 196 patients (22.76%); stage II, 112 pa-
tients (13.0%); stage III, 391 patients (45.41%); and stage
IV, 162 patients (18.81%) (Table 3). The postoperative
complication rate was 3.36% (29/861 cases). It included
localized pleural effusion (15 cases), prolonged air leaks
(5 days) (9 cases), subcutaneous emphysema (3 cases),
pneumonia (1 case), and transient Bernard-Horner syn-
drome (1 case). All complications resolved spontaneously.
Mean time to removal of chest tubes was 4.7 days (range
4-10 days). Mean hospital stay was 5.6 days (range 4-12
days). At discharge from the hospital, a moderate-to-severe
paresthesia was described by 114 patients (13.24%). Short-
term follow-up (1 month) was available in all 861 patients
(100%). At 1 month after the operation, only 16 patients
(1.85%) described paresthesia as being moderate to severe.
Paresthesia spontaneously resolved in all patients within 6
months after the operation. A total of 564 (65.5%) patients
had returned to occupational activities within 21 days and
786 (91.28%) patients within 30 days. An intermediate-term
follow-up was completed in 805 (93.49%) patients. The
mean follow-up was 52.5 months (range 10-110 months). A
follow-up longer than 60 months was available for 285
patients. The overall recurrence rate was 1.73% (14/805).
TABLE 3. Recurrences according to Vanderschueren’s
stage
Stage of PSP No. Patients at follow-up Recurrence (%)
Stage I 196 181 4 (2.18%)
Stage II 112 109 3 (2.75%)
Stage III 391 367 5 (1.36%)
Stage IV 162 148 2 (1.35%)
PSP, Stage of pneumothorax.Among 805 patients included in the follow-up, mean age
324 The Journal of Thoracic and Cardiovascular Surgery ● Febrwas 28.12 years in patients in whom PSP did not recur and
29.71 years in patients in whom it did recur (P.75). Patients
were divided into two groups according to the surgical
treatment: group A (talc poudrage only, stages I and II, 290
patients) and group B (talc poudrage plus stapling of the
blebs/bullae, stages III and IV, 515 patients) (Table 2). The
8-year freedom from recurrence was 96.87% and 98.61%,
respectively, in group A and group B; difference calculated
by log-rank test was not significant (P.10). The recurrence
rate was 2.41% (7/290) in group A and 1.359% (7/515) in
group B (2 value1.207389; P.27; odds ratio 0.56; 95%
confidence intervals 0.20-1.62). Data regarding patients
passing each follow-up time point and patients lost to
follow-up or having a recurrence at each time point are
shown in Table 4 and Figure 1.
With regard to smoking, 12 recurrences occurred in
smokers (12/471 [2.54%]) and 2 occurred in nonsmokers
(2/334 [0.598%]) (2 value 4.343785; P.037; odds ratio
0.24; 95% confidence intervals 0.06-0.93). Recurrences oc-
curred within 12 months in 2 patients (stage IV and stage I),
between 12 and 24 months in 10 patients (stage I: 3; stage
TABLE 4. Patients lost to follow-up or having a recurrence
at each follow-up time point







0 0 2 10 1 1 0 0 0 0 0 14
No. of patients
lost to FUP
0 12 9 7 8 13 7 0 0 0 0 56
PT, Pneumothorax; FUP, follow-up.
Figure 1. Maximum time-point follow-up for each of the 805
patients with a complete follow-up.
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months, respectively, in the remaining 2 patients (stage II
and stage III) (Tables 4 and 5). Recurrences were loculated
in 11 patients (78.57%), almost total in 3 patients, and were
treated by re-VATS (9 cases), chest drainage (3 cases), and
observation (2 cases).
Twenty-six patients (15 male, 11 female) with a
follow-up longer than 60 months underwent respiratory
function tests: forced expiratory volume in 1 second, forced
vital capacity, and diffusing capacity for carbon monoxide
were within normal ranges (80% or more than predictive
value) in all 26 patients.
Discussion
PSP typically occurs in young male adults with a peak
age incidence of 20 to 30 years.1,2 Additional risk factors
are cigarette smoking and an asthenic physiognomy.3 No
precipitating causes can usually be identified. Most epi-
sodes occur at rest. The role of atmospheric pressure or
weather changes is unclear.10,11 Recurrences as well as
first contralateral pneumothorax, bilateral spontaneous
pneumothorax, spontaneous hemothorax, persistent air
leak (5-7 days of tube drainage) or failure to com-
pletely re-expand after drainage of intercostals, and pro-
fessions at risk are clear indications for surgery.4 There is
still a matter of debate regarding the type of surgery. The
great majority of the last reported papers favor the min-
imally invasive VATS approach even if, comparing ran-
domized trials, VATS can only be associated with shorter
length of hospital stay or use of pain medication than
thoracotomy with a comparable complication profile and
success rate.5 An obvious better cosmetic result has also
been claimed by most authors.4 Some authors report that
chronic pain can still afflict up to 63% of patients after
VATS pleurodesis.12-15 Paresthesia resolved spontane-
ously in almost all patients: in our series, 114 patients
(13.24%) described moderate-to-severe paresthesia at
discharge from the hospital, but only 16 patients (1.85%)
at 1 month, and nobody described residual paresthesia 6
months after the operation.9 As previously re-
TABLE 5. Recurrence rates in studies of VATS treatment o
First author Year No. Follow
Present experience 2005 805 52
Ayed7 2003 100 48
Gossot23 2003 111 36
Lang-Lazdunski14 2003 167 84
Margolis18 2003 156 62
Tschopp19 2002 59 60
Cardillo16 2000 432 38
VATS, Videothoracoscopy; PSP, primary spontaneous pneumothorax.ported,16 most recurrences occur within 2 years from
The Journal of Thoracisurgery: this interval should be regarded as the high-risk
window for patients treated for pneumothorax.
In the light of our previous reported experiences4,16
and of the results reported in the present series, we
believe VATS to be an excellent technique for the treat-
ment of recurrent and complicated PSP and talc poudrage
to be the preferred tool for inducing pleurodesis (Table
5).
The overall recurrence rate reported in our series (1.73%)
is much less than the 9% reported by Kennedy and Sahn17
in a meta-analysis published in 1994. Most recent arti-
cles4,18-23 dealing with VATS treatment of PSP have re-
ported a lower failure rate ranging from 0% to 5% (Table 5).
These results are comparable with the failure rate (0.4%-
0.5%) reported with standard thoracotomy or transaxillary
minithoracotomy.20-22 There are no data to assess the opti-
mal dosage schedule of talc. The reported dosage ranges
from 2 to 10 g. There are no controlled trials to state that
higher dosages of talc are more effective in inducing pleu-
rodesis.2 In our experience, we nebulized in the pleural
cavity 2 g of talc and we believe there is no reason to use a
higher dosage of talc with such technique.4,16
With regard to the concern with the use of talc in
young patients, we believe that oncologic risk can be
excluded reasonably by the use of asbestos-free talc
according to a survey of Chappel,24 and coauthors. The
risk of adult respiratory distress syndrome (ARDS)
claimed by some authors25 has not been confirmed in our
series of 861 patients treated in a 9-year period. The risk
may be related to the size of talc particles.5 The Italian
standard (length of fibers  50 m) seems to be a
protective factor for ARDS. Empyema, never reported in
our experience, may be related to technique used for the
sterilization of talc.19,26 Respiratory failure has never
been observed in our series: clinical follow-up did not
reveal any case of respiratory failure in the overall series
of 805 patients included in the follow-up. Furthermore,
pulmonary function tests were within normal ranges in a
group of 26 patients with a follow-up longer than 5 years.
The concern regarding the potential long-term (up to 35
P
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 years) effect of talc poudrage on a young person has been
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of 75 patients: they showed only a mild restrictive respi-
ratory impairment at a follow-up of 22 to 35 years.
Regarding the issue of future thoracic surgery in these
patients, we believe that re-entering the chest will be a
big problem either after talc poudrage or after pleurec-
tomy/pleural abrasion. Minor postoperative complica-
tions (3.36%) were reported. Such rate appears to be
much lower than the 10% complication rate reported by
the largest series dealing with transaxillary minithoraco-
thomy.22 The reasons for such a good success rate of our
technique are the great number of surgically treated pa-
tients (861 patients), as to our knowledge this experience
represents the largest published series of surgically
treated PSP in the world literature; the small number of
surgeons (100% of the procedures were performed by 3
consultant thoracic surgeons, M.M., R.G., G.C.); the
absence of a learning curve (our experience with VATS
treatment of pneumothorax started much earlier); the
homogeneity of the technique; and the efficacy of talc in
inducing pleurodesis. The short operative time (14  8
minutes) reported in the present series, not changed by
additional procedures such as stapling or lysis of adhe-
sions, represents an additional protective factor for a low
complication rate. The recurrences showed a statistically
significant relationship with smoking habits of the pa-
tients: 2.54% recurrence rate in smokers versus 0.598%
in nonsmokers (P.037). Some authors28,29 perform blind
apical stapling in patients with no evidence of bullae
(stages I and II). It is our policy to perform only pleu-
rodesis in such patients, and our data confirm this thesis.
Recurrences after VATS talc poudrage are usually locu-
lated and can be managed either by conservative approach
or by redo VATS.16
In conclusion, VATS talc poudrage shows a high success
rate (98.27%) in the treatment of PSP with a very low
morbidity rate (3.36%). Recurrences show a statistically
significant relationship (P.037) with smoking habits, so that
counseling regarding smoking cessation ideally should be
undertaken before and after surgery.
We thank Mrs Laura D’Orlando for performing respiratory
functional studies, and Mrs Rita Pantini, thoracic theater head
nurse.
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Discussion
Dr Douglas E. Wood (Seattle, Wash). Dr Cardillo, first I would
like to congratulate you and your colleagues for a well-done and
impressive study with very large numbers and superb results.
Some surgeons have continued to question the efficacy of
thoracoscopy for managing patients with SPS, but I think that
the results of this paper demonstrate a very low complication
rate and an even lower recurrence rate that matches or exceeds
any other publications on this subject. Dr Cardillo, you have
given evidence that strongly supports the practice of VATS bleb
resection and pleurodesis for SPS, and I would expect that this
is probably a technique favored by the majority of surgeons in
this room. However, your study does not alleviate my concerns
regarding the potential long-term effects of talc pleurodesis on
young persons with several decades of life ahead of them. You
did not show any ill effects for up to 9 years after the procedure,
but do you have any information on the possible natural history
of talc in the pleural space over 40, 50, or 60 years? Do you
have any concern that a progressive restrictive fibrothorax may
develop in these patients over longer periods of follow-up?
Some percentage of these patients are also likely to require
thoracic surgery in the distant future. Do you have any idea
what findings or difficulty to predict for a future generation of
thoracic surgeons trying to resect a lung cancer in one of these
patients 40 years later?
I applaud your results, but I wonder whether you might be able
to achieve equivalent or very similar results with mechanical
pleurodesis and avoid the theoretical complications of talc in the
pleural space over several decades. You have a high-volume
center. Would it be possible to conduct a randomized trial to
examine the difference between pleurodesis techniques?
Dr Cardillo. Thank you, Dr Wood. We have, of course, no
idea regarding the very long-term effect of talc. This is a
long-term study, but maximum follow-up is 100 months, which
is still not enough. The function tests we have performed in
patients with a long-term follow-up over 5 years showed that
this is not really a restrictive disease. We have no preoperative
data. We should compare the results of the pulmonary function
tests with the standard of these patients. We have done this in
a small series of patients and the results were within normal
range. Obviously we are concerned about long-term results.
Furthermore, in a small group we have performed high-resolu-
tion computed tomography as a follow-up (not discussed it in
this paper), and we have not seen any impressive change. There
was a thickening of the pleural line, but it was a very small
thickening. We have observed this change in some patients who
were willing to undergo computed tomography.
The Journal of ThoraciRegarding thoracic surgery in these patients, of course it will
be a big problem in the future. However, we do not have to
compare these patients with normal subjects. We have to com-
pare patients who have had talc poudrage with patients who
have undergone mechanical pleurodesis, such as pleural abla-
tion or pleurectomy. In our opinion, there is not a big difference
between opening the chest in a patient who underwent pleural
ablation (and that means bleeding) or in a patient who under-
went pleurectomy or talc poudrage.
Dr Allen. Could you do a randomized trial?
Dr Cardillo. That would be a good idea. However, if one
compares the different techniques of pleurodesis up until now,
the results in the literature seems to indicate that talc poudrage
is preferable. Of course, if possible, a randomized study would
be optimal.
Dr Carlos Saldarriaga (Medellin, Colombia). There were 283
women in your study. How many patients with catamenial pneu-
mothorax or diaphragmatic pleural syndrome did you have in your
series and how did you treat these patients?
Dr Cardillo. Catamenial pneumothorax has been occasion-
ally found in our series. In these patients you have to carefully
evaluate the diaphragm, looking for some endometrial tissue.
Really, I think we have included only one or two patients with
catamenial pneumothorax, but in our series we have not found
in any patient endometrial tissue along the diaphragm or along
the pleura.
Dr Malcolm M. DeCamp (Boston, Mass). I enjoyed your
report very much. It is certainly a tremendous large-volume series
that sort of dwarfs the other reports by threefold or fourfold.
I have two questions, the first pertaining to indications for
the patients with persistent air leak. How long is persistent?
How many days will you wait for an air leak to resolve before
you would suggest surgery? Second, would you elaborate on the
postoperative management? You said it was your practice in
this retrospective series to leave the chest tubes for 4 or 5 days.
What are the criteria now other than resolution of air leak
before you will remove the chest tube?
Dr Cardillo. In our opinion, a leak persisting for 4 to 5 days
is a long-term air leak. When we started our experience, we
decided to wait at least 5 days before doing the operation in
patients with an SPS, but with time we are changing our minds.
Now we wait 4 and, in some cases, 2 days before doing the
operation. If the lung is well inflated, then we can wait a little
longer, but if the lung is not well inflated, even after 2 days, I
think it is time for surgery.
Regarding the removal time, in accordance with a study of
Dr Boutin, in the beginning we decided to leave the tube in
place at least 5 days, even if the lung was well inflated and there
was no air leak. Now I think we wait 4 days, but not less than
4 days. This is our rule.
Dr Walter Weder (Zurich, Switzerland). You did not men-
tion as a possible concern that these talc fibers are found in all
organs—in the brain, in the heart, in the muscle, in the kidney—
and this has been shown in animal studies and in autopsies also.
Is this not a concern for you? Do you inform these patients that
these fibers go to all organs?
Dr Cardillo. Thank you, Dr Weder. Talc embolization was
described by Dr West either in animals or in human beings in a
c and Cardiovascular Surgery ● Volume 131, Number 2 327
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in the Current Opinion in Pulmonary Medicine in 2004 a paper
regarding the issue of systemic embolization of talc. He works
at the Oxford Pleural Diseases Unit in the United Kingdom, and
he has a great experience: in his paper he wrote that the problem
of systemic embolization is not yet clarified. So we do not know
the ramifications. This problem may even be related to the
diameter of the talc particles. When we have the results of the
ongoing trial on the safety of talc, we will have more data to
address this issue.
Dr David Waller (Leicester, United Kingdom). Dr Cardillo,328 The Journal of Thoracic and Cardiovascular Surgery ● Febrthis condition. You have also shown that a third of the patients
do not need resection of the blebs. What is your opinion of the
treatment of this condition by pulmonologists by the so-called
medical thoracoscopy?
Dr Cardillo. Thank you, Dr Waller.
In my country we do not let pulmonologists treat pneumo-
thorax. Only thoracic surgeons are allowed to do thoracoscopy.
I work in a hospital in which there are many pulmonologists.
They do bronchoscopy, they do pleuroscopy, but we absolutely
do not let them to do thoracoscopy. So we are the only doctors
treating pneumothorax in my hospital. I do not know aboutyou have shown that pleurectomy may not be needed to treat other institutions.
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